Skip To Main Content
Amit Bar-Or on Muck Rack

Amit Bar-Or

As seen in: Nature, Wiley Online Library, Memory Studies, SAGE Publishing, Cell Press, The Lancet, Pediatrics, medRxiv, Neurology, Citeline and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Amit

Contact Amit, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria

|
By Jiwon Oh, Frederik Barkhof, Amit Bar-Or, Timothy Coetzee, Massimo Filippi, Cristina Granziera, Yael Hacohen, Bernhard Hemmer, Orhun Kantarci, Ho Jin Kim, Christine Lebrun-Frenay, Xavier Montalban, Ellen M Mowry, Daniel Ontaneda, Alexandre Prat, Daniel S. Reich, Alex Rovira, Pascal Sati, Aksel Siva, Andrew Solomon, Maria Pia Sormani, Bruno Stankoff, Mar Tintoré, Anthony L. Traboulsee, Anneke van der Walt, Heinz Wiendl, Peter A Calabresi, Olga Ciccarrelli
| Nature Verified
The 2024 revision of the McDonald diagnostic criteria is an important step toward earlier and more inclusive diagnosis of multiple sclerosis. Realizing its full potential will require continued refinement of biomarkers, disease stratification and clinical trial approaches.
Open in Who Shared Issue with article?

The gut microbiome in pediatric-onset acquired demyelinating syndromes by myelin oligodendrocyte glycoprotein antibody status

|
By Wendy Tsai, Amit Bar-Or, Charles Bernstein
| Multiple Sclerosis and Related Disorders Verified
Keywords gut microbiome gut dysbiosis demyelination myelin oligodendrocyte glycoprotein antibody pediatric acquired demyelinating syndromes Get full text access Log in, subscribe or purchase for full access. REFERENCES 1. Tremlett, H. ∙ Bauer, K.C. ∙ Appel-Cresswell, S. ... The gut microbiome in human neurological disease: A review Ann Neurol. 2017; 81:369-382 2. Correale, J. ∙ Hohlfeld, R. ∙ Baranzini, SE. The role of the gut microbiota in multiple sclerosis Nat Rev Neurol. 2022; 18:544-558 3.
Open in Who Shared Issue with article?

Ublituximab demonstrates sustained benefit for relapsing MS in interim open-label analysis

|
By Isabella Hornick, Shenaz Bagha Verified, Amit Bar-Or
| Citeline Verified
Key takeaways: Adults either continued to receive ublituximab or switched from teriflunomide to ublituximab in this 3-year open-label extension study. The annualized relapse rate in the continued group was 0.02 at year 5. Among adults with relapsing MS who received ublituximab, the annualized relapse rate continued to drop with up to 5 years of treatment, according to an interim open-label extension study analysis published in JAMA Neurology.
Open in Who Shared Issue with article?
See all 45 licensed articles (69 Total)